Sun Pharmaceutical Gets CDSCO Panel Nod To import, market plaque psoriasis drug Tildrakizumab injection Dr. Divya Colin2 March 2025 6:00 PM ISTNew Delhi: Pharmaceutical major Sun Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Tildrakizumab Sustains Long-Term Efficacy for Scalp Psoriasis Treatment, reveals research Dr Riya Dave1 Jan 2025 8:15 PM ISTResearchers have established that tildrakizumab, an anti-interleukin-23 p19 antibody, can be used to maintain long-term efficacy and safety for...
Sun Pharma presents new clinical efficacy, safety data in severe dermatological conditions at 2024 EADV Congress Ruchika Sharma27 Sept 2024 3:51 PM ISTMumbai: Sun Pharmaceutical Industries Limited has announced that it will present abstracts across its dermatology portfolio at the 33rd European...
Tildrakizumab effective and safe therapy for patients with psoriasis: Study Jacinthlyn Sylvia4 April 2024 7:00 PM ISTA recent comprehensive study unveiled the real-world evidence of the effectiveness and safety of a biological drug, tildrakizumab, in treating...
Sun Pharma Gets CDSCO Panel Nod to Study Tildrakizumab Injection 100 mg/ ml Dr. Divya Colin16 Feb 2024 6:00 PM ISTNew Delhi: The drug major Sun Pharma has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Tildrakizumab linked to improved outcomes in plaque psoriasis patients Jacinthlyn Sylvia10 July 2023 9:30 AM ISTAlmirall, a global biopharmaceutical company specializing in medical dermatology, has announced significant progress in the treatment of...
Sponsor should submit rescue management plan: CDSCO Panel Tells Sun Pharma Over Psoriasis Drug Tildrakizumab Susmita Roy18 Jan 2023 6:00 PM ISTNew Delhi: Granting the permission to conduct the proposed study of Tildrakizumab 100mg/ml, the Subject Expert Committee (SEC) functional under the...
Tildrakizumab therapy proves beneficial for Plaque Psoriasis Dr. Kamal Kant Kohli3 Oct 2022 8:00 PM ISTITALY: Tildrakizumab was found to be beneficial for up to 36 weeks in treating moderate-to-severe plaque psoriasis, according to a new study published...
Conduct Phase III bridging CT: CDSCO Panel tells Sun Pharma over psoriasis drug Tildrakizumab Dr. Divya Colin5 Sept 2022 6:00 PM ISTNew Delhi: Denying the request to import and market monoclonal antibody Tildrakizumab Injection 100 mg/ml with a local clinical trial waiver, the...
Present more data on unmet medical need for Tildrakizumab: CDSCO Panel tells Sun pharma Dr. Divya Colin20 March 2022 12:30 PM ISTNew Delhi: In response to the drug-major Sun Pharma's phase 3 protocol for immunomodulator Tildrakizumab, the Subject Expert Committee (SEC)...
Sun Pharma gets Japanese nod to Plaque Psoriasis drug ILUMYA Ruchika Sharma30 Jun 2020 11:30 AM ISTThe drug offers a new treatment option with only one injection every 12 weeks for Japanese patients who struggle every day with the chronic nature of...
Sun Pharma inks exclusive pact with Hikma to distribute ILUMYA in Middle East, North Africa Ruchika Sharma16 Jun 2020 11:41 AM ISTILUMYAâ„¢ (tildrakizumab) is a USFDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque...
